The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene? by Maria Teresa Valenti et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
The effect of bisphosphonates on gene expression: GAPDH as a 
housekeeping or a new target gene?
Maria Teresa Valenti1, Francesco Bertoldo1, Luca Dalle Carbonare*1, 
Giuseppe Azzarello2, Sonia Zenari1, Mirko Zanatta1, Elena Balducci2, 
Orazio Vinante2 and Vincenzo Lo Cascio1
Address: 1Medicina Interna D, Department of Biomedical and Surgical Sciences, University of Verona, Italy and 2Department of Oncology and 
Hematologic Oncology - Noale Hospital, Italy
Email: Maria Teresa Valenti - valenti.lab.oncnoale@inwind.it; Francesco Bertoldo - francesco.bertoldo@univr.it; Luca Dalle 
Carbonare* - luca.dallecarbonare@univr.it; Giuseppe Azzarello - azzarello.med.oncnoale@inwind.it; Sonia Zenari - sonieka@libero.it; 
Mirko Zanatta - mirkozanatta@libero.it; Elena Balducci - balducci.lab.oncnoale@inwind.it; Orazio Vinante - Vinante.med.oncnoale@inwind.it; 
Vincenzo Lo Cascio - vincenzo.locascio@univr.it
* Corresponding author    
Abstract
Background: RT-PCR has been widely used for the analysis of gene expression in many systems,
including tumor samples. GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) has been
frequently considered as a constitutive housekeeping gene and used to normalize changes in
specific gene expression. However, GAPDH has been shown to be up-regulated in many cancers
and down-regulated by chemotherapic drugs. Bisphosphonates, potent inhibitors of bone
resorption, have recently shown a direct and indirect antitumor effect in vitro and in animal models.
They exert their effects mainly by inhibiting the mevalonate pathway but also by modulating the
expression of many genes not only in osteoclasts but also in cancer cells.
Methods: We evaluated GAPDH gene expression by real time RT PCR in breast (MCF-7 and
T47D) and prostate (PC3 and DU-145) cancer cell lines treated with amino and non-amino
bisphosphonates.
Results: Our results showed that amino-bisphosphonates significantly decrease in a dose-
dependent manner the expression of GAPDH gene.
Conclusion: Therefore, GAPDH is inaccurate to normalize mRNA levels in studies investigating
the effect of bisphosphonates on gene expression and it should be avoided. On the other hand, this
gene could be considered a potential target to observe the effects of bisphosphonates on cancer
cells.
Background
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) is
well known for its glycolytic function of converting D-
Glyceraldeide-3-phosphate to 1,3-bisphosphoglycerate
and it has been commonly considered as a constitutive
housekeeping gene. It is widely used as a control RNA in
Northern Blotting and in RT-PCR analysis and recently in
real time RT-PCR.
Published: 03 March 2006
BMC Cancer 2006, 6:49 doi:10.1186/1471-2407-6-49
Received: 11 October 2005
Accepted: 03 March 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/49
© 2006 Valenti et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7
(page number not for citation purposes)
BMC Cancer 2006, 6:49 http://www.biomedcentral.com/1471-2407/6/49In some experimental systems its expression is constant at
different times and after experimental manipulation [1].
In breast cancer cells treated with endoxifen GAPDH was
used to normalize the expression data of the progesterone
receptor mRNA [2]. In addition, GAPDH was the best con-
trol gene in the apoptosis pattern on the myeloid cell lines
incubated with Camptothecin investigated by real time
RT-PCR [3].
However, there is overwhelming evidence suggesting that
its use as an internal standard is inappropriate [4]. Growth
hormone, oxidative stress and the tumour suppressor
TP53 have all been shown to activate its transcription,
which can also be induced in endothelial cells [5]. Con-
versely, retinoic acid down-regulates GAPDH transcrip-
tion in adipocytes [6]. Furthermore, it has been observed
that GAPDH mRNA expression was not normal in some
tumour samples and its distribution exhibited a wide
range of values. GAPDH mRNA was over-expressed in the
poorly differentiated BT-20 cell line and the treatment of
these cells with 1,25-dihydroxyvitamin D3 (1,25-
(OH)2D3) stimulated GAPDH mRNA expression in a
dose- and time-dependent manner [7]. A significant
increase in GAPDH expression was observed when MCF-
7 cells were stimulated with several factors as oestradiol,
insulin growth factor 1 (IGF1) and basic fibroblast growth
factor (bFGF) [8]. In addition, it has been observed that
the GAPDH was up-regulated in rat hepatomas [9], malig-
nant murine cell lines [10] and human prostate carci-
noma [11].
GAPDH was also widely utilized as a control gene in stud-
ies conducted in the last decade to elucidate by RT-PCR
the cellular effects of bisphosphonates, not only on oste-
oclasts or osteoblasts, but also on tumor cells [12,13].
Bisphosphonates (BPs), synthetic analogs of pyrophos-
phate, are potent inhibitors of bone resorption through
the inhibition of osteoclast activity and recruitment
[14,15]. They are used in many metabolic bone diseases.
Furthermore, recent studies have demonstrated that BPs
have an anti-tumour activity too, as highligthed by a
reduced skeletal tumour burden and a slower progression
of bone lesions in animal models [16]. BPs inhibit prolif-
eration, cell adhesion to non-mineralised bone matrices
and induce the apoptosis of a variety of human tumour
cell lines in vitro [17-20]. Most of the BPs pharmacologi-
cal activities have been related to inhibition of the meval-
onate pathway [21], but the modulation of relative
expression of a variety of genes implicated in osteoclast,
osteoblast and tumour cell function has recently been
reported [22-24]. On this basis and since the GAPDH is
commonly used as housekeeping gene, also in studies
using bisphosphonates, and since it is upregulated in
many cancer (7–9,11) and downregulated by chemother-
apic drugs (6), we assessed the effects, if any, of some
bisphosphonates commonly used in cancer bone disease




Human prostatic cancer cell lines (PC-3 and DU-145) and
human breast cancer cell lines (MCF-7 and T-47D) were
purchased from the American Type Culture Collection
(ATTC Rockville, MD, USA). The cells were maintained at
37°C in a humidified atmosphere with 5% CO2 in
DMEM-F12 containing 2 mM L glutamine, 10% fetal




phonate), clodronate (tetrahydrate dichloromethylene-
bisphosphonate, disodium), and pamidronate (3-amino-
1-hydroxypropylidene-bisphosphonate acid, 2Na) were
purchased from Calbiochem. Zoledronate (1-hydroxy-
2,1-imidazol-1-yl-ethylidene bisphosphonic acid) was
kindly provided by Novartis. The neutralized sodium salts
of BPs were dissolved in sterile double distilled H2O at a
final concentration of 100 mM. Stock solutions were aliq-
uoted and kept at -20°C for long term storage.
Cells from 80% confluent cultures were washed with PBS
and treated with trypsin/EDTA. Cells were plated at 1 ×
106 in 25 cm2 flask and incubated for 24 h at 37°C, allow-
ing adhesion of the cells to the new culture plates. Cells
were treated for 48 h with BPs concentrations of 100, 50,
and 10 µM in DMEM/F12 containing 5% FBS. For each
concentration three separate flasks were treated.
Total RNA extraction
Before RNA extraction apoptotic cells were cut out by har-
vesting medium for each fask. Adherent cells were washed
twice with PBS and trypsinized; the cell pellets were col-
lected by centrifugation at 1000 g for 10 min at 4°C. Total
RNA was extracted from each cell culture flask using the
RNAeasy minikit (Quiagen) with DNAse I treatment. The
amount of extracted RNA was quantified by measuring
the absorbance at 260 nm. The purity of the RNA was
checked by measuring the ratio of the absorbance at 260
and 280 nm, where a ratio ranging from 1.8–2.0 was
taken to be pure. The absence of degradation of the RNA
was confirmed by RNA electrophoresis on a 1.5% agarose
gel containing ethidium bromide.
Reverse transcription
First-strand cDNA was generated from 1 µg of each flask
using the High-Capacity cDNA Archive Kit, with random
hexamers, (Applied Biosystems PE) according to the man-Page 2 of 7
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volumes and stored at -80°C.
Real time PCR
PCR was performed in a total volume of 50 µl containing
1x Taqman Universal PCR Master mix, no AmpErase UNG
and 5 µl of cDNA; pre-designed, Gene-specific primers
and probe sets for each gene (GAPDH; Hs99999905-m1)
(Beta 2 microglobulin (B2M); Hs99999907) were
obtained from Assay-on-Demand Gene Expression Prod-
ucts (Applied Biosystems). The real time amplifications
included 10 minutes at 95°C (AmpliTaq Gold activation),
followed by 40 cycles at 95°C for 15 seconds and at 60°C
for 1 minute. As previously reported, the Ct value corre-
lates to the starting quantity of target mRNA [25]. PCR
efficiencies were calculated with a relative standard curve,
derived from a four cDNA dilution series in triplicate and
gave regression coefficients greater than 0.98 and efficien-
cies greater than 96%. To normalize the GAPDH mRNA
expression from sample to sample in RNA input, quality
and reverse transcriptase efficiency, we amplified the
housekeeping gene B2M. The B2M endogenous/internal
control gene was abundant and remained constant, in
proportion to total RNA, among the samples. The GAPDH
and B2M ratio represented the normalized GAPDH (the
GAPDH/B2M ratio).
Standard curves
The relative standard curves were obtained using the
GAPDH and B2M gene primers and probes in singleplex,
amplified with 10, 20, 40 and 80 ng of total RNA, respec-
tively for each control cell line. Each sample was run in
triplicate. The curves obtained for each cell line showed a
linear relationship between RNA concentration and the Ct
value of PCR real time for both GAPDH gene and B2M
gene.
We selected the ∆Rn in the exponential phase of amplifi-
cation plots to determine the Ct values and to obtain the
linearity of calibration curves.
Statistical analysis
Results are expressed as mean ± S.E.M. Student's paired t-
test was used to evaluate differences between the sample
of interest and its respective control. The Wilcoxon test
was used for nonparametric data. For analysis of dose
responses, multiple measurement ANOVA followed by
Newman-Keuls as a post-hoc analysis was performed. A
probability value < 0.05 was considered statistically signif-
icant. Analyses were applied to experiments carried out at
least three times. Statistical analyses were performed using
Statgraphics Plus, version 5 (Manugistics, Inc, Rockville,
MD).
Results
Our results showed that BPs decrease, in a dose-depend-
ent manner, the expression of the GAPDH gene.
In PC-3 cells at 10 µM, the lowest dose tested, only Zoledr-
onate significantly lowered the gene expression with
respect to control (p < 0.001), whereas Alendronate and
Pamidronate significantly down-regulate GAPDH gene
expression at a concentration of 50 (p < 0.001 and p <
0.005, respectively) and 100 µM (p < 0.001). Comparing
the effects among the different BPs, Zoledronate induced
a greater inhibition of GAPDH gene expression at concen-
trations of 10 µM with respect to the Pamidronate (p <
0.01) and Alendronate (p < 0.05). Zoledronate lowered
significantly the GAPDH gene expression at a concentra-
tion of 50 µM with respect to the Pamidronate (p < 0.05).
At a concentration of 100 µM, amino-bisphosphonates
showed a similar inhibition of GAPDH gene expression
(Figure 1A).
Alendronate and Zoledronate induced a significant down-
regulation at 10 µM with respect to control (p < 0.05 and
p < 0.001, respectively) in DU-145 cell line. At the doses
of 50 and 100 µM all the amino-BPs tested significantly
lowered GAPDH gene expression with respect to control
(p < 0.001). Zoledronate at concentrations of 10, 50 and
100 µM significantly down-regulated GAPDH gene
expression with respect to Pamidronate and Alendronate
at the same doses (p < 0.001). (Figure 1B).
In the T-47D cells Alendronate and Pamidronate signifi-
cantly lowered GAPDH gene expression with respect to
control in a dose dependent manner with all the doses
tested (p < 0.001), whereas Clodronate down-regulated
expression only at 100 µM (p < 0.05) (Figure 2A). How-
ever, Alendronate and Pamidronate at 10, 50 and 100 µM
significantly decreased GAPDH gene expression with
respect to all the doses of Clodronate (p < 0.001). At 10
µM Alendronate significantly down-regulated the gene
expression with respect to Pamidronate at the correspond-
ing concentration (p < 0.05).
We found similar results in MCF-7 cells. With all the doses
Alendronate and Pamidronate significantly down-regu-
lated GAPDH gene expression with respect to control in a
dose dependent manner (p < 0.001), whereas Clodronate
decreased, even if not significantly, this expression only at
100 µM. Alendronate and Pamidronate significantly
down-regulated the GAPDH gene expression with respect
to Clodronate at the same concentrations (p < 0.001) (Fig-
ure 2B).
Discussion
In the present study, we have quantified by real time RT
PCR the effect of the BPs on the expression of the GAPDHPage 3 of 7
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cancer cells (MCF-7; T-47D). Our results show a signifi-
cant dose-dependent down-regulation of GAPDH gene
expression after treatment of different cancer cell lines
with different amino-BPs. Our results also indicate that
Zoledronate was the most powerful bisphosphonate,
whereas Clodronate, a non-amino bisphosphonate,
exerted significant effect on GAPDH gene expression only
at the highest concentration tested. This is, to our knowl-
edge, the first report on the effects of BPs on GAPDH gene
expression.
Normalized GAPDH gene expression data in T-47D (Fig.2A) and MCF-7 (Fig.2B) breast cancer cellsFigure 2
Normalized GAPDH gene expression data in T-47D (Fig.2A) and MCF-7 (Fig.2B) breast cancer cells. Control was used as cali-
brator. Amino-BPs (  Alendronate,  Pamidronate) significantly down-regulated the GAPDH expression with respect to 
control in a dose-dependent manner, whereas Non-Amino-BPs (  Clodronate) down-regulated this expression at 100 µM 
only in T-47D breast cancer cell line. * p < 0.001 vs control; # p < 0.05 vs control; § p < 0.001 vs Clodronate
Normalized GAPDH gene expression data in PC-3 (Fig.1A) and in DU-145 (Fig.1B) prostate cancer cellsFigure 1
Normalized GAPDH gene expression data in PC-3 (Fig.1A) and in DU-145 (Fig.1B) prostate cancer cells. Control was used as 
calibrator. Fig.1A: In PC-3 and DU-145 cells amino-bisphosphonates (  Pamidronate,  Alendronate,  Zoledronate) low-
ered in a dose-dependent manner the GAPDH gene expression. * p < 0.001 vs control; # p < 0.005 vs control; § p < 0.05 vs 
control.Page 4 of 7
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showed the up-regulation of the expression of collagenase
3 [12], sialoprotein [26], TNF-α [27] TNF-α Converting
Enzyme [28], osteoprotegerin [22], ALP and OC genes
[29], by BPs. On the other hand, RANKL [30,31], PTHrp
[32], osteopontin [33], Calcitonin receptor [29] were
down-regulated. We may speculate that there could be
two main reasons for the wide use of GAPDH gene as a
housekeeping gene. The first being a general agreement
that BPs act almost exclusively through the inhibition of
mevalonate pathway, as confirmed by the evidence that
GGOH and FOH, final products of mevalonate pathway,
can completely reverse BPs effects [34]. However, some
authors have documented effects independent from
mevalonate pathway inhibition [35]. The second reason is
that the large use of semiquantitative RT-PCR obscures the
quantitative effects, such as the action of BPs on the
expression of a single gene (also in the case of a control
gene).
Our original observation has some interesting implica-
tions. First of all, as GAPDH mRNA expression is down-
regulated in a dose-dependent manner by amino-BPs and
we could speculate that every time a dose-dependent gene
up-regulation is reported, it could be the effect of the con-
comitant down-regulation of the control gene expression,
or it could be, at least, overestimated. On the contrary, the
down-regulation of the housekeeping gene could obscure
the detection of a possible specific gene down-regulation.
A further consideration is that GAPDH could be consid-
ered as a novel target gene for BPs, showing not only a sen-
sitive down-regulation but also reflecting the well
accepted rank of relative in vitro and in vivo potency
between amino and non-amino BPs and within amino-
BPs [21].
It was shown that GAPDH is able to constitute a ternary
complex with DNA and saframycin-related compound
that induces a toxic response in cells. The demonstration
that a specific binding interaction occurs between
GAPDH, duplex DNA, and several members of the
saframycin class of antiproliferative agents suggests
GAPDH as a potential target for chemotherapeutic inter-
vention [36]. GAPDH has a complex and evolving role in
the nucleus, where it seems to act as a monomer [37].
GAPDH has been identified as a component of a multi-
protein nuclear complex that recognized oligonucleotides
incorporating the antileukemic agent thioguanosine [38],
although GAPDH has not been shown to bind directly to
the thioguanosine-modified DNA. Monomeric GAPDH
has also been found as the main component of a multi-
protein nuclear complex involved in transcriptional co-
activation of the histone 2B promoter, required for S
phase progression in the cell cycle [39].
These data raise the possibility that, at least in part, the
direct effect of amino-BPs on cancer cells could be medi-
ated by GAPDH down-regulation. Interestingly, by utiliz-
ing real time PCR, GAPDH mRNA has been down-
regulated by many antineoplastic drugs [36,40] and it has
been related to apoptosis [41].
This study was designed to investigate the possible effects
of BPs on GAPDH mRNA expression, and to explore the
reliability of GAPDH as a housekeeping gene in real time
RT-PCR analysis. Therefore, the data obtained do not
allow the definition of a specific mechanism of action of
amino-BPs through GAPDH down-regulation and we can
only speculate that BPs could affect vitality in cancer cells
in other ways apart from through the inhibition of the
mevalonate pathway, i.e. through the down-regulation of
GAPDH.
Conclusion
The use of GAPDH as a control gene, in particular in stud-
ies investigating the effects of BPs on bone or cancer cells,
seems to be inappropriate and RT-PCR data on the effects
of BPs in cancer cells should be reviewed by a quantitative
approach using real time PCR, with a different housekeep-
ing gene.
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